Antifibrinolytics (lysine analogues) for the prevention of bleeding in patients with haematological disorders

Low-, medium- and high-dose steroids with or without aminocaproic acid in adult hematopoietic SCT patients with diffuse alveolar hemorrhage

“…7 ACA is an antifibrinolytic agent classically used intravenously to control perioperative bleeding, mainly in cardiac surgery. [28][29][30][31] To our knowledge, the only previous study of i.v. adjunctive ACA for DAH was performed by Wanko et al…”

Predicting death from kala-azar: construction, development, and validation of a score set and accompanying software

“…Heparin use is not supported by evidence and must be avoided in such a complex situation. Two new candidates for the treatment of DIC are thrombomodulin and the older tranexamic acid but still lack evidence of effi cacy (47) (48) . Finally, patients with hemorrhage and jaundice should have additional and proper treatment with vitamin K. When facing such uncertainty, clinical trials with these drugs or new candidates should be urgently performed in patients with kala-azar and hemorrhage.…”

“…This may indicate that milder cases worsen additively, but an exponential increase occurs after a certain point, suggesting interactivity between different organs or systems, which refl ects the systemic nature of severe kalaazar infl ammation, evolving to progressive multiple organ dysfunction, followed at the end by death. The complexity of the many mediators and the multiple organ involvement indicate that referral to a higher level of medical attention for organ protection and life support measures are critical decisions while waiting for the slow action of specifi c anti-Leishmania therapy and the prolonged infl ammation period (48) (49) . Possible rules of thumb for model use at bedside would be infant referral from primary care to hospital care when the child's risk of death is greater than the expected 10% mortality.…”

Management of respiratory symptoms in paediatric palliative care

“…Evidence from adult studies suggests a role for antifibrinolytics (e.g. tranexamic acid) in the prevention of bleeding and in reducing platelet transfusions in patients with haematological disorders, although studies are limited [69]. There are no available studies in paediatric palliative care, but given the potential benefit (although limited evidence) demonstrated in adult studies, antifibrinolytics should be considered on an individual patient basis.…”